Marinus Pharma CS (MRNS) 1.76 $MRNS Marinus App
Post# of 273254
Posted On: 09/22/2016 1:02:28 AM
Marinus Pharma CS (MRNS) 1.76 $MRNS
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
GlobeNewswire - Wed Sep 07, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z. Fischer to its Board of Directors.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:15PM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2016.
MRNS: 1.76 (-0.06)
Marinus Stock Down on Dismal Phase III Data on Ganaxolone
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 8:46AM CDT
Marinus (MRNS) announced that it will discontinue the development of ganaxolone for the treatment of adult focal onset seizures.
MRNS: 1.76 (-0.06), ANIP: 65.12 (+0.28), PFE: 34.28 (+0.47), BMY: 55.93 (+0.37)
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
GlobeNewswire - Mon Jun 13, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will be participating in the Bank of America Merrill Lynch 2016 Healthcare Conference taking place May 10th -12th at the Encore at Wynn, Las Vegas, Nevada.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals posts 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Monday reported a loss of $7.2 million in its first quarter.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2016.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Data Presented at the American Academy of Neurology Annual Meeting
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the intravenous (IV) formulation of its CNS-selective GABAA modulator, ganaxolone, for the treatment of status epilepticus. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
GlobeNewswire - Tue Apr 12, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts featuring Marinus's intravenous (IV) formulation of its CNS-selective GABAA modulator, ganaxolone, have been selected for oral and poster presentation at the 68 American Academy of Neurology (AAN) Annual Meeting, to be held April 15-21, 2016 at the Vancouver Convention Centre in Vancouver, BC, Canada.
MRNS: 1.76 (-0.06)
Partial Seizure Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/8mqxzx/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Partial Seizure Overview - Therapeutics Development - Pipeline Products for Partial Seizure - Overview - Pipeline Products for Partial Seizure - Comparative Analysis - Partial Seizure - Therapeutics under Development by Companies - Partial Seizure - Therapeutics under Investigation by Universities/Institutes - Partial Seizure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Partial Seizure - Products under Development by Companies - Partial Seizure - Products under Investigation by Universities/Institutes - Partial Seizure - Companies Involved in Therapeutics Development - Advicenne Pharma - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/8m...al_seizure
MRNS: 1.76 (-0.06), CPRX: 1.09 (+0.03), NVS: 81.52 (+0.46)
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
GlobeNewswire - Wed Jan 27, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will participate in the Canaccord Genuity 2016 Rare Disease, BioPharma One-on-One Day, on Tuesday, February 2, 2016 at the Omni Berkshire Place in New York.
MRNS: 1.76 (-0.06)
Fragile X Syndrome - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlgx9v/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Fragile X Syndrome Overview - Therapeutics Development - Pipeline Products for Fragile X Syndrome - Overview - Pipeline Products for Fragile X Syndrome - Comparative Analysis - Fragile X Syndrome - Therapeutics under Development by Companies - Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes - Fragile X Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Fragile X Syndrome - Products under Development by Companies - Fragile X Syndrome - Products under Investigation by Universities/Institutes - Fragile X Syndrome - Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - AMO Pharma Limited - Confluence Pharmaceuticals LLC - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Sage Therapeutics - Selvita SA - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mlgx9v/fragile_x
MRNS: 1.76 (-0.06), ADHD: 4.72 (+0.11), LLY: 80.87 (+0.99), ZYNE: 11.92 (-0.10)
Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Unavailability of Standard Diagnostic Methods to Identify PTSD Hindering Growth
M2 - Thu Jan 14, 5:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/2gr933/global) has announced the addition of the "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" report to their offering. The report identifies strategic alliances as one of the key trends in the Global Post-traumatic Stress Disorder Therapeutics Market. This takes place in form of licensing and collaboration, where companies will help each other in the development and commercialization of drugs in different regions. The report predicts further growth in this market, at a CAGR of 1.09%, over the forecasted period. This is based on the increasing number of cases of accidents and violence around the world. Stress levels in individuals are rising worldwide because of: - The rise in conflicts between different countries - Domestic and social violence. The report finds that those in the military are particularly affected. And, the report states that the unavailability of standard diagnostic methods to identify PTSD is hindering growth. Key Questions Answered in this Report: - What will the market size be in 2019 and what will the growth rate be? - What are the key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - GlaxoSmithKline plc - Pfizer Inc. - Otsuka Pharmaceutical Co. Ltd. - Abbott Laboratories - Addex Therapeutics - AstraZeneca - Azevan Pharmaceuticals - Baylor Research Institute - Cerecor - Chugai Pharmaceutical - Dart NeuroScience - Dr. Reddy's Laboratories - Edgemont Pharmaceuticals - Eli Lilly - F. Hoffmann-La Roche - Forest Laboratories - H. Lundbeck - Humanetics Pharmaceuticals - Intra-Cellular Therapies - Janssen Pharmaceuticals - Luye Pharma - Marinus Pharmaceuticals - Nanotherapeutics - Naurex - Neurocrine Biosciences - Novartis Pharmaceuticals - Suven - Synchroneuron - Takeda Pharmaceutical - Teva Pharmaceutical - Tonix Pharmaceuticals Report Structure: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Product Profiles 06. Introduction 07. PTSD Overview 08. Pipeline Analysis 09. Market Landscape 10. Market Segmentation by Class of Drug 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and Their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and Their Impact 19. Vendor Landscape 20. Global PTSD Therapeutics Market: Key Takeaways 21. Key Vendor Analysis 22. Other Reports in This Series For more information visit http://www.researchandmarkets.com/research/2gr933/global
ABT: 41.92 (+0.34), NBIX: 54.22 (-0.41), MRNS: 1.76 (-0.06), PFE: 34.28 (+0.47), ITCI: 40.89 (-2.70), LLY: 80.87 (+0.99), GSK: 43.21 (+0.15), NVS: 81.52 (+0.46)
How it All Plays Out - Free Research Reports on Hill International, Marinus Pharmaceuticals, Ampio Pharmaceuticals and Cutera
ACCESSWIRE - Fri Dec 18, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hill International Inc. (NYSE: HIL), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), Ampio Pharmaceuticals Inc. (NYSE: AMPE) and Cutera Inc. (NASDAQ: CUTR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HIL: 4.49 (+0.06), MRNS: 1.76 (-0.06), AMPE: 0.89 (+0.01), CUTR: 11.86 (+0.37)
Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures
GlobeNewswire - Wed Dec 16, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The Company anticipates announcing top-line results from the study in mid-2016.
MRNS: 1.76 (-0.06)
Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting
GlobeNewswire - Mon Dec 07, 8:10AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented additional responder analysis data from the Phase 2 clinical trial of ganaxolone as an adjunctive treatment in 147 randomized adults with focal onset seizures at the 69 Annual Meeting of the American Epilepsy Society, December 6, 2015, at the Pennsylvania Convention Center in Philadelphia, PA.
MRNS: 1.76 (-0.06)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dk2pfp/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Azevan Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eli Lilly and Company - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Marinus Pharmaceuticals, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Polleo Pharma Limited - Synchroneuron Inc. - Tonix Pharmaceuticals Holding Corp. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/dk...ttraumatic
NBIX: 54.22 (-0.41), TNXP: 0.72 (+0.02), MRNS: 1.76 (-0.06), CPRX: 1.09 (+0.03), VNDA: 15.56 (+0.27), PFE: 34.28 (+0.47), ITCI: 40.89 (-2.70), LLY: 80.87 (+0.99), OMER: 11.51 (+0.10), CUR: 0.31 (unch)
Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise
GlobeNewswire - Thu Dec 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. Dr. McCormick has more than 15 years of regulatory strategy and submissions experience at major pharmaceutical firms, including Shire and Pfizer. Both individuals will report to Marinus's Chief Medical Officer, Albena Patroneva, M.D.
MRNS: 1.76 (-0.06)
Origins of Technical Movement, Pricing Tomorrow - Research on Zynerba Pharmaceuticals, Emergent Capital, Marinus Pharmaceuticals, and Comstock Resources
ACCESSWIRE - Mon Nov 23, 7:41AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Emergent Capital Inc. (NYSE: EMG), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) and Comstock Resources Inc. (NYSE: CRK). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MRNS: 1.76 (-0.06), CRK: 7.28 (+0.23), EMG: 3.21 (-0.03), ZYNE: 11.92 (-0.10)
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
GlobeNewswire - Wed Sep 07, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z. Fischer to its Board of Directors.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:15PM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2016.
MRNS: 1.76 (-0.06)
Marinus Stock Down on Dismal Phase III Data on Ganaxolone
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 8:46AM CDT
Marinus (MRNS) announced that it will discontinue the development of ganaxolone for the treatment of adult focal onset seizures.
MRNS: 1.76 (-0.06), ANIP: 65.12 (+0.28), PFE: 34.28 (+0.47), BMY: 55.93 (+0.37)
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures
GlobeNewswire - Mon Jun 13, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will be participating in the Bank of America Merrill Lynch 2016 Healthcare Conference taking place May 10th -12th at the Encore at Wynn, Las Vegas, Nevada.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals posts 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Monday reported a loss of $7.2 million in its first quarter.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2016.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Data Presented at the American Academy of Neurology Annual Meeting
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the intravenous (IV) formulation of its CNS-selective GABAA modulator, ganaxolone, for the treatment of status epilepticus. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016.
MRNS: 1.76 (-0.06)
Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting
GlobeNewswire - Tue Apr 12, 6:30AM CDT
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts featuring Marinus's intravenous (IV) formulation of its CNS-selective GABAA modulator, ganaxolone, have been selected for oral and poster presentation at the 68 American Academy of Neurology (AAN) Annual Meeting, to be held April 15-21, 2016 at the Vancouver Convention Centre in Vancouver, BC, Canada.
MRNS: 1.76 (-0.06)
Partial Seizure Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/8mqxzx/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Partial Seizure Overview - Therapeutics Development - Pipeline Products for Partial Seizure - Overview - Pipeline Products for Partial Seizure - Comparative Analysis - Partial Seizure - Therapeutics under Development by Companies - Partial Seizure - Therapeutics under Investigation by Universities/Institutes - Partial Seizure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Partial Seizure - Products under Development by Companies - Partial Seizure - Products under Investigation by Universities/Institutes - Partial Seizure - Companies Involved in Therapeutics Development - Advicenne Pharma - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/8m...al_seizure
MRNS: 1.76 (-0.06), CPRX: 1.09 (+0.03), NVS: 81.52 (+0.46)
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day
GlobeNewswire - Wed Jan 27, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it will participate in the Canaccord Genuity 2016 Rare Disease, BioPharma One-on-One Day, on Tuesday, February 2, 2016 at the Omni Berkshire Place in New York.
MRNS: 1.76 (-0.06)
Fragile X Syndrome - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlgx9v/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Fragile X Syndrome Overview - Therapeutics Development - Pipeline Products for Fragile X Syndrome - Overview - Pipeline Products for Fragile X Syndrome - Comparative Analysis - Fragile X Syndrome - Therapeutics under Development by Companies - Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes - Fragile X Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Fragile X Syndrome - Products under Development by Companies - Fragile X Syndrome - Products under Investigation by Universities/Institutes - Fragile X Syndrome - Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - AMO Pharma Limited - Confluence Pharmaceuticals LLC - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Sage Therapeutics - Selvita SA - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mlgx9v/fragile_x
MRNS: 1.76 (-0.06), ADHD: 4.72 (+0.11), LLY: 80.87 (+0.99), ZYNE: 11.92 (-0.10)
Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Unavailability of Standard Diagnostic Methods to Identify PTSD Hindering Growth
M2 - Thu Jan 14, 5:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/2gr933/global) has announced the addition of the "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" report to their offering. The report identifies strategic alliances as one of the key trends in the Global Post-traumatic Stress Disorder Therapeutics Market. This takes place in form of licensing and collaboration, where companies will help each other in the development and commercialization of drugs in different regions. The report predicts further growth in this market, at a CAGR of 1.09%, over the forecasted period. This is based on the increasing number of cases of accidents and violence around the world. Stress levels in individuals are rising worldwide because of: - The rise in conflicts between different countries - Domestic and social violence. The report finds that those in the military are particularly affected. And, the report states that the unavailability of standard diagnostic methods to identify PTSD is hindering growth. Key Questions Answered in this Report: - What will the market size be in 2019 and what will the growth rate be? - What are the key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - GlaxoSmithKline plc - Pfizer Inc. - Otsuka Pharmaceutical Co. Ltd. - Abbott Laboratories - Addex Therapeutics - AstraZeneca - Azevan Pharmaceuticals - Baylor Research Institute - Cerecor - Chugai Pharmaceutical - Dart NeuroScience - Dr. Reddy's Laboratories - Edgemont Pharmaceuticals - Eli Lilly - F. Hoffmann-La Roche - Forest Laboratories - H. Lundbeck - Humanetics Pharmaceuticals - Intra-Cellular Therapies - Janssen Pharmaceuticals - Luye Pharma - Marinus Pharmaceuticals - Nanotherapeutics - Naurex - Neurocrine Biosciences - Novartis Pharmaceuticals - Suven - Synchroneuron - Takeda Pharmaceutical - Teva Pharmaceutical - Tonix Pharmaceuticals Report Structure: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Product Profiles 06. Introduction 07. PTSD Overview 08. Pipeline Analysis 09. Market Landscape 10. Market Segmentation by Class of Drug 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and Their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and Their Impact 19. Vendor Landscape 20. Global PTSD Therapeutics Market: Key Takeaways 21. Key Vendor Analysis 22. Other Reports in This Series For more information visit http://www.researchandmarkets.com/research/2gr933/global
ABT: 41.92 (+0.34), NBIX: 54.22 (-0.41), MRNS: 1.76 (-0.06), PFE: 34.28 (+0.47), ITCI: 40.89 (-2.70), LLY: 80.87 (+0.99), GSK: 43.21 (+0.15), NVS: 81.52 (+0.46)
How it All Plays Out - Free Research Reports on Hill International, Marinus Pharmaceuticals, Ampio Pharmaceuticals and Cutera
ACCESSWIRE - Fri Dec 18, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hill International Inc. (NYSE: HIL), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), Ampio Pharmaceuticals Inc. (NYSE: AMPE) and Cutera Inc. (NASDAQ: CUTR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HIL: 4.49 (+0.06), MRNS: 1.76 (-0.06), AMPE: 0.89 (+0.01), CUTR: 11.86 (+0.37)
Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures
GlobeNewswire - Wed Dec 16, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The Company anticipates announcing top-line results from the study in mid-2016.
MRNS: 1.76 (-0.06)
Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting
GlobeNewswire - Mon Dec 07, 8:10AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented additional responder analysis data from the Phase 2 clinical trial of ganaxolone as an adjunctive treatment in 147 randomized adults with focal onset seizures at the 69 Annual Meeting of the American Epilepsy Society, December 6, 2015, at the Pennsylvania Convention Center in Philadelphia, PA.
MRNS: 1.76 (-0.06)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dk2pfp/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Azevan Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eli Lilly and Company - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Marinus Pharmaceuticals, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Polleo Pharma Limited - Synchroneuron Inc. - Tonix Pharmaceuticals Holding Corp. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/dk...ttraumatic
NBIX: 54.22 (-0.41), TNXP: 0.72 (+0.02), MRNS: 1.76 (-0.06), CPRX: 1.09 (+0.03), VNDA: 15.56 (+0.27), PFE: 34.28 (+0.47), ITCI: 40.89 (-2.70), LLY: 80.87 (+0.99), OMER: 11.51 (+0.10), CUR: 0.31 (unch)
Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise
GlobeNewswire - Thu Dec 03, 6:30AM CST
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. Dr. McCormick has more than 15 years of regulatory strategy and submissions experience at major pharmaceutical firms, including Shire and Pfizer. Both individuals will report to Marinus's Chief Medical Officer, Albena Patroneva, M.D.
MRNS: 1.76 (-0.06)
Origins of Technical Movement, Pricing Tomorrow - Research on Zynerba Pharmaceuticals, Emergent Capital, Marinus Pharmaceuticals, and Comstock Resources
ACCESSWIRE - Mon Nov 23, 7:41AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Emergent Capital Inc. (NYSE: EMG), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) and Comstock Resources Inc. (NYSE: CRK). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MRNS: 1.76 (-0.06), CRK: 7.28 (+0.23), EMG: 3.21 (-0.03), ZYNE: 11.92 (-0.10)
(0)
(0)Scroll down for more posts ▼